tradmap

TSHA Taysha Gene Therapies, Inc.

$6.40 +3.39%

Healthcare · Biological Products, (No Diagnostic Substances)

Taysha Gene Therapies, Inc. (TSHA) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.8 billion. Shares last traded at $6.40, 20.0% below their 52-week high. Over the past year the stock is up 150.0%. Net profit margin is -1115.3%, below the peer median of 6.3%. Revenue grew 17.3% year over year.

Market Cap
$1.8B
Shares Out
287.4M
EPS (TTM)
$-0.63
P/E Ratio
P/S Ratio
188.18
P/B Ratio
8.68
Dividend / Share
Dividend Yield
52-Week High
$8.00
52-Week Low
$2.25
Volume
203,716
Avg Vol (3m)
196,504.333

Performance

1W
+14.70%
1M
+23.43%
3M
+40.50%
6M
+9.97%
YTD
+21.67%
1Y
+150.00%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
61.52
SMA (50)
$5.96
SMA (200)
$4.88
Price vs SMA50
+7.42%
Price vs SMA200
+31.05%
ATR (14)
$0.40

Financials

Revenue
$10M
Net Income
$-109M
Gross Margin
Operating Margin
-1130.6%
Net Margin
-1115.3%
Return on Equity
-51.4%
Return on Assets
-36.3%
Current Ratio
14.04
Debt / Equity
0.23
Revenue Growth (YoY)
+17.3%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.12 2026-05-06
FY 2025 $-0.34 2026-03-19
Q3 2025 $-0.26 2025-11-04
Q2 2025 $-0.17 2025-08-12
Q1 2026 $-0.08 2026-05-06
FY 2025 $-0.36 2026-03-19

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

TSHA vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
188.18 / 5.21 med
+3510% premium
Net margin vs peers
-1115.3% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.